An insight on targets and patented drugs for chemotherapy of chagas disease

Recent Patents on Anti-Infective Drug Discovery

Volumn 2, Issue 1, 2007, Pages 19-51

  Duschak, Vilma G ^a   Couto, Alicia S ^b  

^a Ministerio de Salud de la Nación   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Chagas disease; Drug targets; Natural and synthetic inhibitor compounds; Trypanosoma cruzi

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ALBACONAZOLE; ALENDRONIC ACID; AMIODARONE; AMPHOTERICIN B LIPID COMPLEX; AROMATIC NITRO COMPOUND; BENZNIDAZOLE; CATHEPSIN K INHIBITOR; ETIDRONIC ACID; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NIFUROXIME; NIFURTIMOX; NITRILE; PAMIDRONIC ACID; POSACONAZOLE; PROTEINASE INHIBITOR; PYRIDINIUM DERIVATIVE; QUINUCLIDINE DERIVATIVE; RAVUCONAZOLE; RISEDRONIC ACID; TERBINAFINE; THIOCYANIC ACID DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; TIPIFARNIB; UNINDEXED DRUG;

BIOCHEMISTRY; CHAGAS DISEASE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LEISHMANIASIS; MALARIA; NONHUMAN; OSTEOPOROSIS; PATENT; PRIORITY JOURNAL; REVIEW; STEROL SYNTHESIS; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ANIMALS; ARGININE KINASE; BIOLOGICAL PRODUCTS; CHAGAS DISEASE; ENZYME INHIBITORS; ERGOSTEROL; GLYCOLYSIS; HUMANS; LIPIDS; ORGANELLES; PATENTS AS TOPIC; PENTOSE PHOSPHATE PATHWAY; PROTEASE INHIBITORS; PURINES; SIALIC ACIDS; SULFHYDRYL COMPOUNDS; TERPENES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 34248375271     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489107779561625     Document Type: Review

References (349)

1. Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiasis. Lancet 2003; 362(9394): 1469-80.
2. WHO World Health Org Tech rep Ser. 2002; 905: i-vi, 1-109.
3. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002; 97(5): 603-12.
4. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev 2005; 18(1): 12-29.
5. Panamerican Health Organization Status of Chagas disease in the region of Americas. Epidemiologic bulletin. Pan American Health Organization, 1984 Washington, DC.
6. Matsumoto SC, Labovsky V, Roncoroni M, et al. Retinal dysfunction in patients with chronic Chagas disease is associated to anti- Trypanosoma cruzi antibodies that cross-react with rhodopsin. FASEB J 2006; 20(3): 550-52.
7. Tarleton RJ. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001; 31(5-6): 550-54.
8. Riveiro dos Santos G, Nishiya AS, Sabino EC, Chamone DF, Saez-Alquezar A. An improved PCR-based strategy for the detection of Trypanosoma cruzi in human blood samples. Ann Trop Med Parasitol 1999; 93(7): 689-94.
9. Manawa ES, Bastos SF, Camargo ME, et al. Evaluation of recombinant antigens for serodiagnosis of Chagas disease in South and Central America. J Clin Microbiol 1999; 37(5): 1554-60.
10. Hernandez Marin M, Hernandez Spengler I, Ramos Martinez G, Pozo Pena L. Chimeric synthetic peptides as antigens for detection of antibodies to Trypanosoma cruzi. Biochem Biophys Res Commun 2006; 339(1):89-92.
11. Rodríguez Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97(1): 3-24.
12. Garcia S, Ramos CO, Senra JFV, et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob Agents and Chemother 2005; 49(4):1521-28.
13. Apt W, Arribada A, Zulantay I, et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 2005; 99(8): 733-41.
14. Fournet A, Munoz V. Natural products as trypanocidal, antileishmanial and antimalarial drugs. Curr Top Med Chem 2002; 2(11): 1215-37.
15. Morel CM. Neglected diseases: under-funded research and inadequate health interventions. Can we change this reality? EMBO Rep 2003; 4: 35-38.
16. Morel CM, Acharya T, Broun D, et al. Health innovation networks to help developing countries address neglected diseases. Science 2005; 309(5733): 401-04.
17. El-Sayed NM, Myler PJ, Bartholomeu DC, et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005; 309(5733): 409-15.
18. Nguyen B, Lee MP, Hamelberg D, et al. Strong binding in the DNA minor groove by an aromatic diamidine with a shape that does not match the curvature of the groove. J Am Chem Soc 2002; 124: 13680-81.
19. Hannon GJ. RNA interference. Nature 2002; 418: 244-51.
20. Denli AM, Hannon GJ. RNAi: an ever-growing puzzle. Trends Biochem Sci 2003; 28(4): 196-201.
21. Cazzulo JJ. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr Top Med Chem 2002; 2(11): 1261-71.
22. Cazzulo JJ, Cazzulo Franke BM, Martinez J, Franke de Cazzulo BM. Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochim Byophys Acta 1990; 1037(2): 186-91.
23. Eakin AE, Mills AA, Harth G, McKerrow JH, Craik CS. The sequence, organization, and expression of the major cysteine proteinase (cruzain) from Trypanosoma cruzi. J Biol Chem 1992; 267: 7411-20.
24. Murta ACM, Persechini PM, de Souto Padrón T, de Souza W, Guimaraes JA, Scharfstein J. Structural and functional identification GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase. Mol Biochem Parasitol 1990; 43: 27-38.
25. Cazzulo JJ, Labriola C, Parussini F, Duschak VG, Martinez J, Franke de Cazzulo BM. Cysteine proteinases in Trypanosoma cruzi and other trypanosomatid parasites. Acta Chimica Slovenica 1995; 42: 409-18.
26. Parusini F, Duschak VG, Cazzulo JJ. Membrane-bound cysteine proteinase isoforms in different developmental stages of Trypanosoma cruzi. Cell Mol Biol 1998; 44(3): 513-19.
27. Duschak VG, Barboza M, Garcia GA, Lammel EM, Couto AS, Isola EL. Novel cysteine proteinase in Trypanosoma cruzi metacyclogenesis. Parasitology 2006; 132(3):345-55.
28. Cazzulo JJ, Stoka V, Turk V. The major cysteine proteinase of Trypanosoma cruzi: A valid target for chemotherapy of Chagas disease. Curr Pharm Des 2001; 7(12):1143-56.
29. Duschak VG, Ciaccio M, Nassert JR, Basombrio MA. Enzymatic activity, protein expression, and gene sequence of cruzipain in virulent and attenuated Trypanosoma cruzi strains. J Parasitol 2001; 87(5): 1016-22.
30. Ramos AM, Duschak VG, Gerez de Burgos NM, et al. Trypanosoma cruzi: cruzipain and membrane-bound cysteine proteinase isoform(s) interacts with human alpha (2)-macroglobulin and pregnancy zone protein. Exp Parasitol 2002; 100(2): 121-30.
31. Duschak VG, Riarte A, Segura EL, Laucella SA. Humoral immune response to cruzipain and cardiac dysfunction in chronic Chagas disease. Immunol Lett 2001; 78(3): 135-42.
32. Barboza M, Duschak VG, Cazzulo JJ, Lederkremer RM, Couto AS. Presence of sialic acid in N-linked oligosaccharide chains and O-linked N-acetylglucosamine in cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Mol Biochem Parasitol 2003; 126: 293-96.
33. Barboza M, Duschak VG, Fukuyama Y, et al. Structural analysis of the N-glycans of the major cysteine proteinase of Trypanosoma cruzi. Identification of sulfated high-mannose type oligosaccharides. FEBS J 2005; 272(15): 3803-15.
34. Harth G, Andrews N, Mills AA, Engel JC, Smith R, McKerrow JH. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol Biochem Parasitol 1993; 58(1): 17-24.
35. Duschak VG, Barboza M, Couto AS. Trypanosoma cruzi: partial characterization of minor cruzipain isoforms non-adsorbed to Concanavalin A-Sepharose. Exp Parasitol 2003; 104(3-4): 122-30.
36. McGrath ME, Eakin AE, Engel JC, et al. The crystal structure of cruzain: a therapeutic target for Chagas disease. J Mol Biol 1995; 247(2): 251-59.
37. Huang L, Brinen LS, Ellman JA. Crystal structures of reversible ketone-based inhibitors of the cysteine protease cruzain. Bioorg Med Chem 2003; 11(1): 21-29.
38. 2+ signaling in mammalian cells. J Cell Biol 1997; 136(3): 609-20.
39. Morty RE, Shih AY, Fulop V, Andrews NW. Identification of the reactive cysteine residues in oligopeptidase B from Trypanosoma brucei. FEBS Lett 2005; 579(10): 2191-96.
40. Lalmanach G, Mayer R, Serveau C, Scharfstein J, Gauthier F. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Biochem J 1996; 318: 395-99.
41. Hernandez AA, Roush WR. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr Opin Chem Biol 2002; 6(4): 459-65.
42. Engel JC, Doyle PS, Hsieh Y, McKenow JH. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998; 88(4):725-34.
43. Engel JC, Doyle PS, Palmer J, Bainton DF, Hsieh I, McKerrow JH. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci 1998; 11: 597-606.
44. McKerrow JH. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int J Parasitol 1999; 29(6): 833-37.
45. Roush WR, Cheng J, Knapp-Reed B, et al. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorg Med Chem Lett 2001; 11: 2759-62.
46. Gotz MG, Caffrey CR, Hansell E, Mc Kerrow JH, Powers JC. Peptidyl allyl sulfones: a new class of inhibitors for clan CA cysteine proteases. Bioorg Med Chem 2004; 12(19):5203-11.
47. Li R, Chen X, Gong B, et al. Structure-based design of parasitic protease inhibitors. Bioorg Med Chem 1996; 4(9): 1421-27.
48. Du X, Hansell E, Engel JC, Caffrey CR, Cohen FE, McKerrow JH. Aryl ureas represent a new class of anti-trypanosomal agents. Chem Biol 2000; 7(9): 733-42.
49. Huang L, Lee A, Ellman JA. Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. J Med Chem 2002; 45(3): 676-84.
50. Choe Y, Brinen LS, Price MS, et al. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorg Med Chem 2005; 13(6): 2141-56.
51. Marquis, R.W., Ru, Y., Veber, D.F., Cummings, M., Thompson, S.K., Yamashita, D.: WO0195911 (2001).
52. Quibell, M., Taylor, S., Grabowska, U., Nilsson, M., Morrison, V.: WO0240462A2 and WO0240462A3 (2002).
53. Quibell, M., Ramjee, M.K: WO02057246A2 and WO02057246A3 (2002).
54. Quibell, M.: WO02057248A2 and WO02057248A3 (2002), WO02057249A1 (2002), WO02057270A1 (2002), CA2436462AA (2002)
55. Quibell, M.: EP1362052A1 (2003), NO20033220A (2003), NO20033220A0 (2003).
56. Quibell, M.: CN1486320A (2004), MX3006224A (2004), ZA0305259A (2004). NZ0526913A (2004).
57. Quibell, M.: Ray, P.C., Watts, J.P.: WO04007501A1 (2004).
58. Lim-Wilb, M., Semple, J.E., Araldi, G.L., Goldman, E.A., Weinhouse, M.I.: WO0248097A1, WO0248097B1 and WO0248097C2 (2002).
59. Quibell, M., Ramjee, M.K.: US20056958358 (2005).
60. Marquis, R.W.Jr., Veber, D.F., Yamashita, D.S.: WO03053331A2 and WO03053331A3 (2003).
61. Jeong, J.U., Yamashita, D.S.: WO03103574A2 and WO03103574A3 (2003); WO03104257A2 and WO03104257A3 (2003); WO03097593A2 and WO03097593A3 (2003).
62. Tew, D.G., Thompson, S.K., Veber, D.F.: WO00217924A1 (2002).
63. Altman, E., Betschart, C., Hayakawa, K., Irie, O., Sakaki, J., Iwasaki, G., Lattmann, R., Missbach, M., Teno, N.: WO04020441A1 (2004).
64. Bondebjerg, J., Fuglsang, H., Naerum, L.:WO04110988A1 (2004).
65. Hickey, E.R., Bekkali, Y., Patel, U.R., Spero, D.M., Thomson, D.S., Young, E.R.: WO02100849A2 and WO02100849A3 (2002).
66. Hickey, E.R., Bekkali, Y., Patel, U.R., Spero, D.M., Thomson, D.S., Young, E.R.: US20066982263 (2000).
67. Sulea, T., Purisima, E.O., Menard, R., Wang, J.: WO03097664A2 and WO03097664A3 (2003).
68. Du X, Guo C, Hartsell E, et al. Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem 2002; 45(13): 2695-707.
69. Chibale K, Musonda CC. The synthesis of parasitic cysteine protease and trypanothione reductase inhibitors. Curr Med Chem 2003; 10(18): 1863-89.
70. Chiyanzu I, Hansell E, Gut J, Roshenthal PJ, McKerrow JH, Chibale K. Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett 2003; 13(20): 3527-30.
71. Fujii N, Mallari JP, Hansell EJ, et al. Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg Med Chem Lett 2005; 15(1): 121-23.
72. Yong V, Schmidtz V, Vannier-Santos MA, et al. Altered expressionof cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases. Mol Biochem Parasitol 2000; 109(1): 47-59.
73. Engel JC, Garcia CT, Hsieh I, Doyle PS, McKerrow JH. Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi. J Cell Sci 2000; 113: 1345-54.
74. Desai PV, Patny A, Sabnis Y, et al. Identification of novel parasitic cysteine protease inhibitors using virtual screening 1. The Chem Bridge database. J Med Chem 2004; 47(26): 6609-15.
75. Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005; 49(12): 5160-61.
76. Greenbaun DC, McMackey Z, Hansell E, et al. Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J Med Chem 2004; 47(12): 3212-29.
77. Leite AC, de Lima RS, Moreira DR, et al. Synthesis, docking, and in vitro activity of thiosemicarbazones, aminoacyl-thiosemicarbazides and acyl-thiazolidones against T. cruzi. Bioorg Med Chem 2006; 14(11): 3749-57.
78. Cohen, F.E., Du, X., Guo, Ch., McKerrow, J.H.: US20056897240 (2005).
79. García MP, Nóbrega, OT, Teixeira, ARL, Sousa, MV, Santana, JM. Characterization of a Trypanosoma cruzi acidic 30 kDa cysteine protease. Mol Biochem Parasitol 1998; 91: 263-72.
80. 2+ - signaling factor for mammalian cells. J Biol Chem 1995; 270(10): 5172-80.
81. Santana JM, Grellier P, Schrevel J, Teixeira AR. A Trypanosoma cruzi-secreted 80 kDa proteinase with specificity for human collagen types I and IV. Biochem J 1997; 325(1):129-37.
82. Vendeville S, Bourel L, Davioud-Charvet E, Grellier P, Deprez B, Sergheraert C. Automated parallel synthesis of a tetrahydroisoquinolin-based library: Potential prolyl endopeptidase inhibitors. Bioorg Med Chem Lett 1999; 9:437-42.
83. Joyeau R, Maoulida C, Guillet C, et al. Synthesis and activity of pyrrolidinyl- and thiazolinidyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oligopeptidase from T. cruzi. Eur J Med Chem 1999; 35: 257-66.
84. Grellier P, Vendeville S, Joyeau R, et al. Trypanosoma cruzi prolyl oligopeptidase Tc80 is involved in nonphagocytic mammalian cell invasion by trypomastigotes. J. Biol Chem 2001; 276: 47078-86.
85. Bal G, Van der Veken P, Antonov D, et al. Prolylisoxazoles: potent inhibitors of prolyloligopetidase with antitrypanosomal activity. Bioorg Med Chem Lett 2003; 13(17): 2875-78.
86. Bastos IM, Grellier P, Martins NF, et al. Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. Biochem J 2005; 338(1): 29-38.
87. Cuevas IC, Cazzulo JJ, Sanchez D. GP63 homologues in Trypanosoma cruzi: surface antigens with metalloprotease activity and a possible role in host cell infection. Infect Immun 2003; 71(10): 5739-49.
88. Paugam A, Bulteau AL, Dupuoy-Camet J, Creuzet C, Friguet B. Characterization and role of protozoan parasite proteasomes. Trends Parasitol 2003; 19(2): 55-59.
89. Gonzalez J, Ramalho-Pinto FJ, Frevert U, et al. Proteasome activity is required for the stage-specific transformation of a protozoan parasite. J Exp Med 1996; 184(5): 1909-18.
90. de Diego JL, Katz JM, Marshall P, et al. The ubiquintin-proteasome pathway plays an essential role in proteolysis during Trypanosoma cruzi remodeling. Biochemistry 2001; 40(4): 1053-62.
91. Palladino, M., Neuteboom, S.T.C., Macherla, V.R.R., Potts, B.C.: WO2005002572A2 and WO2005002572A3 (2005).
92. Steverding D, Spackman RW, Royle HJ, Glenn RJ. Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors. Parasitol Res 2005; 95(1): 73-76.
93. Schaller H. The role of sterols in plant growth and development Prog Lipid Res 2003; 42(3): 163-175.
94. Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, Goad LJ. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 2003; 126(2): 129-42.
95. Quinones W, Urbina JA, Dubourdieu M, Luis Conception J. The glycosome membrane of Trypanosoma cruzi epimastigotes: protein and lipid composition. Exp Parasitol 2004; 106: 135-49.
96. Braga MV, Urbina JA, de Souza W. Effects of squalene synthase inhibitors on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents 2004; 24(1): 72-78.
97. Garzoni LR, Caldera A, Meirelles MN, et al. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int J Antimicrob Agents 2004; 3: 273-85.
98. Urbina JA, Chemotherapy of Chagas' disease: the how and the why. J Mol Med 1999; 77(3): 332-38.
99. Urbina JA, Payares G, Contreras LM, et al. Antiproliferative effects and mechanism of action of SCH56592 against Trypanosoma cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 1998; 42: 1771-77.
100. Urbina JA, Lira R, Visbal G, Bartroli J. in vitro Antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 2000; 44(9): 2498-502.
101. Urbina JA. Chemotheraphy of Chagas disease. Curr Pharm Des 2002; 8(4): 287-95.
102. Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003; 21(1): 27-38.
103. Urbina JA, Payares G, Molina JT, et al. Cure of short-and long-term experimental Chagas disease using D0870. Science 1996; 273: 969-71.
104. Urbina JA, Payares C, Sanoja, et al. Parasitological cure of acute and chronic experimental Chagas disease using a long-acting experimental triazole TAK-187. Acitivity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 2003; 21: 39-48.
105. Docampo R, Schmunis GA. Sterol biosynthesis inhibitors: potential chemotherapeutics against Chagas disease. Parasitol Today 1997; 13: 129-30.
106. Lepesheva GI, Waterman CYP51-the omnipotent P450. Mol Cell Endocrinol 2004; 215: 165-70.
107. Lepesheva GI, Zaitzeva NG, Nes WD, et al. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. J Biol Chem 2006; 281(6): 3577-85.
108. Hanskins EG, Gillespie JR, Aikenhead K, Buckner FS. Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol Biochem Parasitol 2005; 144(1): 68-75.
109. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003; 19: 495-501.
110. Apt W, Aguilera Y, Arribada A, et al. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am J Trop Med Hyg 1998; 59: 133-38.
111. Guedes PMM, Urbina JA, Lana M, et al. Activity of the new derivative Albuconazole against Trypanosoma cruzi in dog hosts. Antimicrob Agents Chemoter 2004; 48(11): 4286-92.
112. Buckner FS, Wilson AJ, White TC, Van Vooris WC. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob Agents Chemother 1998; 42(12): 3245-50.
113. Buckner F, Yokoyama K, Lockman J, et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci USA 2003; 100(25): 15149-53.
114. Hucke O, Gelb MH, Verlinde CL, Buckner FS. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 2005; 48(17): 5415-18.
115. Benaim G, Sanders JM, Garcia-Marchan Y, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 2006; 49(3): 892-99.
116. Jouvert BM, Buckner FS, Matsuda SP. Trypanosome and animal lanosterol synthases use different catalytic motifs. Org Lett 2001; 14: 1957-60.
117. Rose IC, Sharpe BA, Lee RC, et al. Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents. Bioorg Med Chem 1996; 4: 97-103.
118. Buckner FS, Griffin JH, Wilson AJ, Van Voorhis WC. Potent anti- Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob Agents Chemother 2001; 45(4): 1210-15.
119. Oliaro-Bosso S, Ceruti M, Balliano G, Milla P, Rocco F, Viola F. Analogs of squalene and oxidosqualene inhibit oxidosqualene cyclase of Trypanosoma cruzi expressed in Saccharomyces cerevisiae. Lipids 2005; 40(12): 1257-62.
120. Prestwich, G.D., Buckner, F.S., Hinshaw, J.C.: WO0076316A1 (2000).
121. Abe I, Prestwich GD. In Cane DE Ed, Comprehensive natural products chemistry. New York, Elsevier. 1999; 2(10): 267-98.
122. Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997; 114: 91-99.
123. Urbina JA, Concepcion JL, Rangel S, Visbal G, Lira R. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol Biochem Parasitol 2002; 125(1-2): 35-45.
124. Urbina JA, Concepcion JL, Caldera A, et al. in vitro and in vivo Activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 2004; 48(7): 2379-87.
125. Szajnman SH, Yan W, Bayley BN, Docampo R, Elhalem E, Rodriguez JB. Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation. J Med Chem 2000; 43(9): 1826-40.
126. Elhalem E, Bailey BN, Docampo R, Ujvary I, Szajnman SH, Rodriguez JB. Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against Trypanosoma cruzi. J Med Chem 2002; 45(18): 3984-99.
127. Urbina JA, Concepcion JL, Montalvetti A, Rodriguez JB, Docampo R. Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimibrob Agents Chemoter 2003; 47(6): 2047-50.
128. Hiyoshi H, Yanagimachi M, Ito M, et al. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J Lipid Res 2003; 44(1): 128-35.
129. Orenes LS, Gomez R, Jimenez C, et al. Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg Med Chem 2005; 13(10): 3519-29.
130. Orenes Lorente S, Jimenez CJ, Gros L, et al. Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics. Bioorg Med Chem 2005; 13(18): 5435-53.
131. Urbina JA, Lazardi Y, Marchan E, et al. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma cruzi: in vitro and in vivo studies. Antimicrob Agents Chemoter 1993; 37(3): 580-91.
132. Yardley V, Crof SL. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am J Trop Med Hyg 1999; 61(2): 193-97.
133. Hamilton, A.D., Van Vooris, W.C., Yokoyama, K., Buckner, F.S., Ohkanda, J., Gelb, M.: WO03006012A1 (2003).
134. Lockman J., Hamilton, A.D., Gelb, M., Buckner, F.S., Ohkanda, J., Yokoyama, K., Van Vooris, W.C., CA2453396AA (2003).
135. Hamilton, A.D., Van Vooris, W.C., Yokoyama, K., Buckner, F.S., Ohkanda, J., Gelb, M., Lockman J: BR0211098A (2004).
136. Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem 2001; 276(36): 33930-37.
137. Martin MB, Grimley JS, Lewis JC, et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosonta cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 2001; 44(6): 909-16.
138. Garzoni LR, Caldera A, Meirelles M de N, et al. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosonia cruzi. Int J Antimicrob Agents 2004; 23(3): 273-85.
139. Garzoni LR, Waghabi MC, Baptista MM, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents 2004; 23(3): 286-90.
140. Szajnman SH, Montalvetti A, Wang Y, Docampo R, Rodriguez JB. Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. Bioorg Med Chem Lett 2003; 13(19): 3231-35.
141. Szajnman SH, Ravaschino EL, Docampo R, Rodriguez JB. Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg Med Chem Lett 2005; 15(21): 4685-90.
142. Docampo R, Moreno SN. Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites. Curr Drug Targets Infect Disord 2001; 1(1): 51-61.
143. Gabelli SB, McLellan JS, Montalvetti A, Oldfield E, Docampo R, Amzel LM. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins 2006; 62(1): 80-88.
144. Sigman L, Sanchez VM, Turjansky AG. Characterization of the farnesyl pyrophosphate synthase of Trypanosoma cruzi by homology modeling and molecular dynamics. J Mol Graph Model 2006; 25 (3): 345-52.
145. Mansour T. In: Apellido, nombre, Ed, Chemotherapeutic targets in parasites: contemporary strategies. Cambridge University Press. 2002; 90-122.
146. Gelb MH, Van Voohris WC, Buckner FS, et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol 2003; 126(2): 155-63.
147. Karp JE. Farnesyl transferase inhibition in hematologic malignancies. J Natl Compr Canc Netw 2005; 3 (1): 37-40.
148. Esteva MI, Kettler K, Maidana C, et al. Benzophenone-based farnesyl transferase inhibitors with high activity against Trypanosoma cruzi. J Med Chem. 2005; 48(23): 7186-91.
149. Field, M.C., Ali, B.R.S.: WO00105384A3 (2001).
150. Windsor, W.T., Weber, P.C., Stricland, C., Syto, R., Girija-vallabhan, V.M., Kaminski, J.J., Guo, Z.: US2003134846A1 (2003).
151. Krauth-Siegel RL, Inhoff O. Parasite-specific trypanothione reductase as a drug target molecule. Parasitol Res 2003; 90(2): 77-85.
152. Krauth-Siegel RL, Bauer H, Schirmar RH. Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl 2005; 44(5): 690-715.
153. Augustins K, Amssoms K, Yamani A, Rajan PK, Haemers A: Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. Curr Pharm Des 2001; 7(12): 1117-41.
154. Stoppani AO. The chemotherapy of Chagas disease. Medicina (Bs As) 1999; 59(2): 147-65.
155. Henderson GB, Ulrich P, Fairlamb AH, et al. "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc Natl Acad Sci USA 1988; 85(15): 5374-78.
156. Salmon Chemin L, Buisine E, Yardley V, et al. 2- and 3-substituted 1, 4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J Med Chem 2001; 44(4): 548-65.
157. Blumenstiel K, Schoeneck R, Yardley V, Croft SL, Krauth-Siegel RL. Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochem Pharmacol 1999; 58(11): 1791-99.
158. Paulino M, Iribarne F, Dubin M, Aguilera-Morales S, Tapia O, Stoppani AO. The chemotherapy of Chagas' disease: an overview. Mini Rev Med Chem 2005; 5(5): 499-519.
159. Santos AF, Ferraz PA, de Abreu FC, Chiari E, Goulart MO, Sant'Ana AE. Molluscicidal and trypanocidal activities of lapachol derivatives. Planta Med 2001; 67(1): 92-93.
160. De Moura KCG, Emery FS, Neves-Pinto C, et al. Synthesis and trypanocidal activity of naphthoquinones isolated from Tabebuia and heterocyclic derivatives: a review from an interdisciplinary study. J Braz Chem Soc 2001; 12: 325-38.
161. Cuellar MA, Salas C, Cortes MJ, Morello A, Diego Maya J, Preite MD. Synthesis and in vitro trypanocide activity of several polycyclic drimane-quinone derivatives. Bioorg Med Chem 2003; 11(12): 2489-97.
162. De Moura KC, Salomao K, Menna-Barreto RF, et al. Studies on the trypanocidal activity of semi-synthetic pyran [b-4, 3]naphtho [1,2-d]imidazoles from β-lapachone. Eur J Med Chem 2004; 39(7): 639-45.
163. Jorqueira A, Goubea RM, Ferreira VF, et al. Oxyrane derivative of alpha-lapachone is potent growth inhibitor of Trypanosoma cruzi epimastigote forms. Parasitol Res 2006; 99(4): 429-33.
164. Silva RS, Costa EM, Trindade UL, et al. Synthesis of naphthofuranquinones with activity against Trypanosoma cruzi. Eur J Med Chem 2006; 41(4): 526-30.
165. Austin SE, Khan MO, Douglas KT. Rational drug design using trypanothione reductase as a target for anti-trypanosomal and anti-leishmanial drug leads. Drug Des Discov 1999; 16(1): 5-23.
166. Gallwitz H, Bonse S, Martinez-Cruz A, Schichting I, Schumacher K, Krauth-Siegel RL. Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies. J Med Chem 1999; 42(3): 364-72.
167. Farrell NP, Williamson J, McLaren DJ. Trypanocidal and antitumour activity of platinum-metal and platinum-metal-drug dual-fanction complexes. Biochem Pharmacol 1984; 33(7): 961-71.
168. Bonse S, Richards JM, Ross SA, Lowe G, Krauth-Siegel RL. (2, 2′: 6′, 2″-Terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase. J Med Chem 2000; 43(25): 4812-21.
169. Sanchez-Delgado RA, Lazardi K, Rincon L, Urbina JA. Toward a novel metal-based chemotherapy against tropical diseases. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuC12 (clotrimazole)2. J Med Chem 1993; 36(14): 2041-43.
170. Sanchez-Delgado RA, Anzellotti A. Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis. Mini Rev Med Chem 2004; 4(1): 23-30.
171. Lowe, G.: WO0050431A1 (2000).
172. Lee B, Bauer H, Melchers J, et al. Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J Med Chem 2005; 48(23): 7400-10.
173. Otelo L, Vieites M, Boiani L, et al. Novel trypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J Med Chem 2006; 49(11): 3322-31.
174. Gutierrez-Correa J, Fairlamb AH, Stoppani AO. Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radic Res 2001; 34(4): 363-78.
175. Rivarola HW, Paglini Oliva P. Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution. Curr Drug Targets Cardiovasc Haematol Disord 2002; 2(1): 43-52.
176. Rivarola HW, Bustamante JM, Lo Presti S, et al. Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area. Exp Parasitol 2005; 111(2): 80-86.
177. Jacoby EM, Schlichting I, Lantwin CB, Kabsch W, Krauth-Siegel RL. Crystal structure of the Trypanosoma cruzi trypanothione reductase-mepacrine complex. Proteins 1996; 24(1): 73-80.
178. Girault S, Davioud-Charvet E, Salmon L, Berecibar A, Debreu MA, Sergheraert C. Structure-activity relationships in 2-aminodiphenylsulfides against trypanothione reductase from Trypanosoma cruzi. Bioorg Med Chem Lett 1998; 8(10): 1175-80.
179. Girault S, Davioud-Charvet TE, Maes L, et al. Potent and specific inhibitors of trypanothione reductase from Trypanosoma cruzi: bis(2-aminodiphenylsulfides) for fluorescent labeling studies. Bioorg Med Chem 2001; 9(4): 837-46.
180. Bonnet B, Soullez D, Davioud-Charvet E, Landry V, Horvath D, Sergheraert C. New spermine and spermidine derivatives as potent inhibitors of Trypanosoma cruzi trypanothione reductase. Bioorg Med Chem 1997; 5(7): 1249-56.
181. Li Z, Fennie MW, Ganem B, et al. Polyamines with N-(3-phenylpropyl) substituents are effective competitive inhibitors of trypanothione reductase and trypanocidal agents. Bioorg Med Chem Lett 2001; 11(2):251-54.
182. Flohe L, Hecht HJ, Steinert T. Glutathione and trypanothione in parasitic hydroperoxide metabolism. Free Radic Biol Med. 1999; 27(9-10): 966-84.
183. Fournet A, Rojas de Arias A, Ferreira ME, et al. Efficacy of the bisbenzylisoquinoline alkaloids in acute and chronic Trypanosoma cruzi murine model. Int J Antimicrob Agents 2000; 13(3): 189-95.
184. Khan MO, Austin SE, Chan C, et al. Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines. J Med Chem 2000; 43(16): 3148-56.
185. Parveen S, Khan MO, Austin SE, et al. Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide. J Med Chem 2005; 48(25): 8087-97.
186. Aguirre G, Cabrera E, Cerecetto H, et al. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti- Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. Eur J Med Chem 2004; 39(5): 421-31.
187. Aguirre G, Boiani M, Cabrera E, et al. New potent 5-nitrofuryl derivatives as inhibitors of Trypanosoma cruzi growth. 3D-QSAR (CoMFA) studies. Eur J Med Chem 2006; 41(4): 457-66.
188. Meiering S, Inhoff O, Mies J, et al. Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. J Med Chem 2005; 48(15): 4793-802.
189. Wilkinson SR, Obado SO, Mauricio IL, Kelly JM. Trypanosoma cruzi expresses a plant-like ascorbate-dependent hemoperoxidase localized to the endoplasmic reticulum. Proc Natl Acad Sci USA 2002; 99(21): 13453-58.
190. Ravaschino EL, Docampo R, Rodriguez JB. Design, synthesis, and biological evaluation of phosphinopeptides against Trypanosoma cruzi targeting trypanothione biosynthesis. J Med Chem 2006; 49(1): 426-35.
191. Engel JC, Franke de Cazzulo BM, Stoppani AO, Cannata JJ, Cazzulo JJ. Aerobic glucose fermentation by Trypanosoma cruzi axenic culture amastigote-like forms during growth and differentiation to epimastigotes. Mol Biochem Parasitol 1987; 26(1-2): 1-10.
192. Souza DH, Garatt RC, Araujo AP, et al. Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design. FEBS Lett 1998; 424(3): 131-35.
193. Aronov A, Suresh S, Buckner FS, et al. Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci USA 1999; 96(8): 4273-78.
194. Bressi JC, Verlinde CL, Aronov AM, et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem 2001; 44(13): 2080-93.
195. Tomazela DM, Pupo MT, Passador EA, et al. Pyrano chalcones and a flavone from Neoraputia magnifica and their Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase-inhibitory activities. Phytochemistry 2000; 55(6): 643-51.
196. Ladame S, Castilho MS, Silva CH, et al. Crystal structure of Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase complexed with an analogue of 1, 3-bisphospho-d-glyceric acid Eur J Biochem 2003; 270(22): 4574-86.
197. de Marchi AA, Castillo MS, Nascimento PG, et al. New 3-piperonylcoumarins as inhibitors of glycosomal glyceraldehyde-3-phosphate dehydrogenase (gGAPDH) from Trypanosoma cruzi. Bioorg Med Chem 2004; 12(18): 4823-33.
198. Hudock MP, Sanz-Rodriguez CE, Song Y, et al. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem 2006; 49(1): 215-23.
199. Maugeri DA, Cazzulo JJ. The pentose phosphate pathway in Trypanosoma cruzi. FEMS Microbiol Lett 2004; 234(1): 117-23.
200. Igoillo-Esteve MI, Cazzulo JJ. The glucose-6-phosphate dehydrogenase from Trypanosoma cruzi: Its role in the defense of the parasite against oxidative stress. Mol Biochem Parasitol 2006; 149(2): 170-81
201. Pereira CA, Alonso GD, Paveto MC, et al. Trypanosoma cruzi arginine kinase characterization and cloning. A novel energetic pathway in protozoan parasites. J Biol Chem 2000; 275(2): 1495-501.
202. Pereira CA, Alonso GD, Ivaldi S, et al. Arginine metabolism in Trypanosoma cruzi is coupled to parasite stage and replication. FEBS Lett 2002; 526(1-3): 111-14.
203. Paveto C, Guida MC, Esteva MI, et al. Anti-Trypanosoma cruzi activity of green tea (Camellia sinensis) catechins. Antimicrob Agents Chemother 2004; 48(1): 69-74.
204. Silber AM, Colli W, Ulrich H, Alves MJ, Pereira CA. Amino acid metabolic routes in Trypanosoma cruzi: possible therapeutic targets against Chagas' disease. Curr Drug Targets Infect Disord 2005; 5(1): 53-64.
205. Naula C, Parsons M, Mottram JC. Protein kinases as drug targets in Trypanosomes and Leishmania. Biochim Biophys Acta 2005; 1754(1-2): 151-59.
206. Braga MV, de Souza W. Effects of protein kinase and phosphatidylinositol-3 kinase inhibitors on growth and ultrastructure of Trypanosoma cruzi. FEMS Microbiol Lett 2006; 256(2): 209-16.
207. Ariyanayagam MR, Fairlamb AH. Diamine auxotrophy may be a universal feature of Trypanosoma cruzi epimastigotes. Mol Biochem Parasitol 1997; 84(1): 111-21.
208. Majumder S, Wirth JJ, Bitonti AJ, McCann PP, Kierszenbaum F. Biochemical evidence for the presence of arginine decarboxylase activity in Trypanosoma cruzi. J Parasitol 1992; 78(2): 371-74.
209. Menezes D, Valentim C, Oliveira MF, Vannier-Santos MA Putrescine analogue cytotoxicity against Trypanosoma cruzi. Parasitol Research 2006; 98(2): 99-105.
210. Audette, M., Charest-Gaudrealt, R.: US6949679 (2005).
211. Ullman B, Carter D. Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates. Int J Parasitol 1997; 27(2): 203-13.
212. Nakajima-Shimada J, Hirota Y, Aoki T. Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs. Antimicrob Agents Chemother 1996; 40(11): 2455-58.
213. Avila JL, Avila A, Munoz E. Effect of allopurinol on different strains of Trypanosoma cruzi. Am J Trop Med Hyg 1981; 30(4): 769-74.
214. Eakin AE, Guerra A, Focia PJ, Torres-Martinez, Craig SP 3rd. Hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi as a target for structure-based inhibitor design: crystallization and inhibition studies with purine analogs. Antimicrob Agents Chemother 1997; 41(8): 1686-92.
215. Freymann DM, Wenck MA, Engel JC, et al. Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi. Chem Biol 2000; 7(12): 957-68.
216. Wenck MA, Medrano FJ, Eakin AE, Craig SP. Steady-state kinetics of the hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi. Biochim Biophys Acta 2004; 1700 (1): 11-18.
217. Reche P, Arrebola R, Santi DV, Gonzalez Pacanowska D, Ruiz Perez LM. Expression and characterization of the Trypanosoma cruzi dihydrofolate reductase domain. Mol Biochem Parasitol 1996; 76(1-2): 175-85.
218. Gilbert IH. Inhibitors of dihydrofolate reductase in Leishmania and Trypanosomes. Biochim Biophys Acta. 2002; 1587(2-3): 249-57.
219. Chowdhury SF, Guerrero RH, Brun R, Ruiz-Perez L, Pacanowska DG, Gilbert IH. Synthesis and testing of 5-benzyl-2, 4-diaminopyrimidines as potential inhibitors of leishmanial and trypanosomal dihydrofolate reductase. J Enzyme Inhib Med Chem 2002; 17(5):293-302.
220. Pez D, Leal I, Zuccotto F, et al. 2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase. Bioorg Med Chem 2003; 11(22): 4693-711.
221. Khabnadidesh S, Pez D, Musso A, et al. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase. Bioorg Med Cbem 2005; 13(7): 2637-49.
222. Sencovich O, Bhatia V, Garg N, Chattopadhyay D. Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease. Antimicrob Agents Chemother 2005; 49(8): 3234-38.
223. Nare B, Luba J, Hardy LW, Beverley SM. New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology 1997; 114 Suppl: S: 101-10.
224. Schormann N, Pal B, Chattopadhyay D. Expression, purification, crystallization and preliminary crystallographic analysis of recombinant pteridine reductase of Trypanosoma cruzi. Acta Crystallogr D Biol Crystallogr 2001; 57(11): 1671-73.
225. Senkovich O, Pal B, Schormann N, Chattopadhyay D. Trypanosoma cruzi genome encodes a pteridine reductase 2 protein. Mol Biochem Parasitol 2003; 127(1): 89-92.
226. Schormann N, Pal B, Senkovich O, et al. Cristal structure of Trypanosoma cruzi pteridine reductase 2 in complex with a substrate and an inhibitor. J Struct Biol 2005; 152(1): 64-75.
227. Lowe, G.: WO0153276A1 (2001).
228. Lawton P. Purine analogs as antiparasitic agents Expert Opin Ther Patents 2005; 15(8): 987-94.
229. Bottaro, J.C., Schmitt, R.J., Petrie, M.A., Penwell, P.E.: WO0114401A1 (2001).
230. Nara T, Kamei Y, Tsubouchi A, et al. Inhibitory action of marine algae extracts on the Trypanosoma cruzi dihydroorotate dehydrogenase activity and on the protozoan growth in mammalian cells. Parasitol Internat 2005; 54 (1): 59-64.
231. Inaoka DK, Tashamira E, Osanai A. Expression, purification and crystallization of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with orotate. Acta Crystal Sec F Struct Biol Cryst Commun. 2005; 61(10): 875-78.
232. Gonzales-Perdomo M, de Castro SL, Meirelles MN, Goldenberg S. Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob Agents Chemother 1990; 34(9): 1707-14.
233. Abdul-Rahman, S.: US20056967205 (2005).
234. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on Trypanosomes and Leishmania. Proc Natl Acad Sci USA 1995; 92(9): 3726-30
235. Stephens CE, Brun R, Salem MM, et al. The activity of diguandino and 'reversed' diamidino 2, 5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani. Bioorg Med Chem Lett 2003; 13 (12): 2065-69.
236. Werbovetz K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Invest Drugs. 2006; 7(2): 147-57.
237. Boykin, D., Tlidwell, R.R., Wilson, W.D., Perfect, J.R., Stephens, C.E.: WO02057224A2 and WO02057224A3 (2002).
238. Ochola DO, Prichard RK, Lubega GW. Classical ligands bind tubulin of trypanosomes and inhibit their growth in vitro. J Parasitol 2002; 88(3): 600-04.
239. Werbovetz, K., Bhatta Charya, G., Sackett, D., Salem, M.M.: WO03090678A2 and WO03090678A3 (2003).
240. Bukrinsky, M. I., Cerami, A., Ulrich, P., Berger, B.: US20056906076 ( 2005).
241. Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SN. Acidocalcisomes-conserved from bacteria to man. Nat Rev Microbiol 2005; 3(3): 251-61.
242. Lang, H.J., Lanzer, M., Wiesner, J., Sanchez, C., Wunsch, S.E.P.: US20006114393 (2000).
243. Menna-Barreto RF, Henriquez-Pons A, Pinto AV, Morgado-Diaz JA, Soares MJ, De Castro SL. Effect of a beta-lapachone-derived naphthoimidazole on Trypanosoma cruzi: identification of target organelles. J Antimicrob Chemother 2005; 56(6): 1034-41.
244. Montalvetti A, Rohloff P, Docampo RA. A functional aquaporin co-localizes with the vacuolar proton pyrophosphatase to acidocalcisomes and the contractile vacuole complex of Trypanosoma cruzi. J Biol Chem 2004; 279(37): 38673-82.
245. Beitz E. Aquaporins from pathogenic protozoan parasites: structure, function and potential for chemotherapy. Biol Cell 2005; 97(6): 373-83.
246. Wilkinson SR, Prathalingam SR, Taylor MC, Horn D, Kelly JM. Vitamin C biosynthesis in trypanosomes: a role for the glycosome. Proc Natl Acad Sci USA 2005; 102(33): 11645-50.
247. Schenkman S, Chaves LB, Pontes de Carvalho LC, Eichinger D. A proteolytic fragment of Trypanosoma cruzi trans-sialidase lacking the carboxyl-terminal domain is active, monomeric, and generates antibodies that inhibit enzymatic activity. J Biol Chem 1994; 269(11): 7970-75.
248. Frasch AC. Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol Today 2000; 16(7): 282-86.
249. Buschiazzo A, Amaya MF, Cremona ML, Frasch AC, Alzari PM. The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol Cell 2002; 10(4): 757-68.
250. Streicher H, Busse H. Building a successful structural motif into sialylmimetics-cyclohexenephosphonate monoesters as pseudo-sialosides with promising inhibitory properties. Bioorg Med Chem 2006;14 (4):1047-57.
251. Horenstein, B.A., Parr, I.B.: WO9906369A1 (1999).
252. Luo, M., White, C.L.: US20006114386 (2000).
253. Santa Rita SM, Santos Barboza H, Meirelles MN, de Castro SL. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Tropics 2000; 75(2): 219-28.
254. Lira R, Contreras LM, Rita RM, Urbina JA. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 2001; 47(5): 537-46.
255. de Castro SL, Santa Rita RM, Urbina JA, Croft SL. Antiprotozoal lysophospholipid analogues: a comparison of their activity against trypanosomatid parasites and tumor cells. Mini Rev Med Chem 2004; 4(2): 141-51.
256. Santa Rita RM, Lira R, Barbosa HS, Urbina JA, de Castro SL. Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis. J Antimicrob Chemother 2005; 55(5): 780-84.
257. Santa Rita RM, Barbosa HS, de Castro SL. Ultrastructural analysis of edelfosine-treated trypomastigotes and amastigotes of Trypanosoma cruzi. Parasitol Res. 2006; 100(1): 189-90.
258. Jones SM, Urch JE, Brun R, Harwood JL, Berry C, Gilbert IH. Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents. Bioorg Med Chem 2004; 12 (4): 683-92.
259. Couto AS, Caffaro C, Uhrig ML, et al. Glycosphingolipids in Plasmodium falciparum. Presence of an active glucosylceramide synthase. Eur J Biochem 2004; 271(11): 2204-14.
260. Pankova-Kholmyansky I, Flescher E. Potential new antimalarials chemotherapeutics based on sphingolipid methabolism. Chemotherapy 2006; 52: 205-09.
261. Solari AJ, Duschak VG. Intermediate filaments induced by Taxol in cultures of Crithidia fasciculata. Microscopía Electrónica y Biología Celular 1985; 9(2): 163-75.
262. Dantas AP, Barbosa HS, De Castro SL. Biological and ultrastructural effects of the anti-microtubule agent taxol against Trypanosoma cruzi. J Submicrosc Cytol Pathol 2003; 35(3): 287-94.
263. Grellier P, Sinou V, Garreau-de Loubresse N, Bylen E, Boulard Y, Schrevel J. Selective and reversible effects of vinca alkaloids on Trypanosoma cruzi epimastigote forms: blockage of cytokinesis without inhibition of the organelle duplication. Cell Motil Cytoskeleton 1999; 42(1): 36-47.
264. Morello A, Lipchenka I, Cassels BK, Speisky H, Aldunate J, Repetto Y. Trypanocidal effect of boldine and related alkaloids upon several strains of Trypanosoma cruzi. Comp Biochem Physiol Pharmacol Toxicol Endocrinol 1994; 107(3): 367-71.
265. Rivas P, Cassels BK, Morello A, Repetto Y. Effects of some beta-carboline alkaloids on intact Trypanosoma cruzi epimastigotes. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1999; 122 (1): 27-31.
266. Chataing B, Concepcion JL, Lobaton R, Usubillaga A Inhibition of Trypanosoma cruzi growth in vitro by Solanum alkaloids: a comparison with ketoconazole. Planta Med 1998; 64(1): 31-36.
267. Mahiou V, Roblot F, Fournet A, Hocquemiller R. isbenzylisoquinoline alkaloids from Guatteria boliviana (Annonaceae). Phytochemistry 2000; 54(7): 709-16.
268. Ribeiro TS, Freire de Lima L, Previato JO, Mendonca Previato L, Heise N, de Lima ME Toxic effects of natural piperine and its derivatives on epimastigotes and amastigotes of Trypanosoma cruzi. Bioorg Med Chem Lett 2004; 14(13): 3555-58.
269. Gonzalez P, Marin C, Rodriguez-Gonzalez I, et al. Diterpenoid alkaloid derivatives as potential chemotherapeutic agents in American trypanosomiasis. Pharmacology 2006; 76(3): 123-28.
270. del Olmo E, Armas MG, Lopez-Perez JL, et al. Anti-Trypanosoma activity of some natural stilbenoids and synthetic related heterocyclic compounds. Bioorg Med Chem Lett 2001; 11(20): 2755-57.
271. Bronia DH, Pereira BM, Lujan HD, Fretes RE, Fernández A, Paglini PA. Ganglioside treatment of acute Trypanosoma cruzi infection in mice promotes long-term survival and parasitological cure. Ann Trop Med Parasitol 1999; 93(4): 341-50.
272. Fernández Gomez R, Zerrouk H, Sebti F, Loyens M, Benslimane A, Ouaissi MA. Growth inhibition of Trypanosoma cruzi and Leishmania donovani infantum by different snake venoms: preliminary identification of proteins from Cerastes cerastes venom which interact with the parasites. Toxicon 1994, 32(8): 875-82.
273. Stoka AM. Activity of juvenile hormone and juvenile hormone analogues on the growth of Trypanosoma cruzi. J Steroid Biochem Mol Biol 1996; 59(5-6): 495-500.
274. Fichera L, Esteva M, Wimmer Z, Rodríguez JB, Gros EG. Effects of juvenile hormone analogues (JHA) on the development of Trypanosoma cruzi. Z Naturforsch [C] 1995; 50(7-8): 578-80.
275. Rodriguez JB, Docampo R, Gros EG. Sulphur-containing derivatives structurally related to fenoxycarb are potent growth inhibitors against the intracellular form of Trypanosoma cruzi. Int J Antimicrob Agents 2000; 13(3): 215-18.
276. Esteva M, Ruiz AM, Stoka AM. Trypanosoma cruzi: methoprene is a potent agent to sterilize blood infected with trypomastigotes. Exp Parasitol 2002; 100(4): 248-51.
277. Weniger B, Vonthron-Senecheau C, Kaiser M, Brun R, Anton R. Comparative antiplasmodial, leishmanicidal and trypanocidal activities of several biflavonoids. Phytomedicine 2006; 13(3): 176-80.
278. de Castro, Higashi KO. Effect of different formulations of propolis on mice infected with Trypanosoma cruzi. J Ethnopharmacol 1995; 46(1): 55-58.
279. Marcuchi MC, Ferreres F, Garcia-Viguera C, et al. Phenolic compounds from Brazilian propolis with pharmacological activities. J Ethnopharmacol 2001; 74(2): 105-12.
280. Prytzyk E, Dantas AP, Salomao K, et al. Flavonoids and trypanocidal activity of Bulgarian propolis. J Ethnopharmacol 2003; 88(2-3): 189-93.
281. da Silva Cunha IB, Salomao K, Shimizu M, et al. Antitrypanosomal activity of Brazilian propolis from Apis mellifera. Chem Pharm Bull (Tokyo) 2004; 52(5): 602-04.
282. Dantas AP, Olivieri BP, Gomez FH, De Castro SL. Treatment of Trypanosoma cruzi-infected mice with propolis promotes changes in the immune response. J Ethnopharmacol 2006; 103(2): 187-93.
283. De Castro SL, Pinto MC, Pinto AV. Screening of natural and synthetic drugs against Trypanosoma cruzi. 1. Establishing a structure/ activity relationship. Microbios 1994; 78(315): 83-90.
284. Morello A, Pavani M, Garbarino JA. Effects and mode of action of 1, 4-naphthoquinones isolated from Calceolaria sessilis on tumoral cells and Trypanosoma parasites. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995; 112(2): 119-28.
285. Alves TM, Alves R, Romanha AJ, Zani CL, dos Santos MH, Nagem TJ. Biological activities of 7-epiclusianone. J Nat Prod 1999; 62(2): 369-71.
286. Bell A, Monaghan P, Page AP. Peptidyl-prolyl cis-trans isomerases (immunophilins) and their roles in parasite biochemistry, host-parasite interaction and antiparasitic drug action. Int J Parasitol 2006; 36(3): 261-76.
287. Bua J, Ruiz AM, Potenza M, Fichera LE. in vitro Anti-parasitic activity of Cyclosporin A analogs on Trypanosoma cruzi. Bioorg Med Chem Lett 2004; 14(18): 4633-37.
288. Fournet A, Barrios AA, Munoz V. Leishmanicidal and trypanocidal activities of Bolivian medicinal plants. J Ethnopharmacol 1994; 41(1-2): 19-37.
289. Berger I, Passreiter CM, Caceres A, Kukelka W. Antiprotozoal activity of Neurolaena lobata. Phytother Res 2001; 15(4): 327-30.
290. Muelas-Serrano S, Nogal JJ, Martinez-Diaz RA, Escario JA, Martinez-Fernandez AR, Gomez-Barrio A. in vitro Screening of American plant extracts on Trypanosoma cruzi and Trichomonas vaginalis. J Ethnopharmacol 2000; 71(1-2): 101-07.
291. Mafezoli J, Vieira PC, Fernandez JB, da Silva MF, de Albuquerque S. in vitro Activity of Rutaceae species against the trypomastigote form of Trypanosoma cruzi. J Ethnopharmacol 2000; 73(1-2): 335-40.
292. Pizzolatti MG, Koga AH, Grisard EC, Steindel M. Trypanocidal activity of extracts from Brazilian Atlantic Rain Forest plant species. Phytomedicine 2003; 10(5): 422-26.
293. Truiti MC, Ferreira IC, Zamuner ML, Nakamura CV, Serragiotto MH, Souza MC. Antiprotozoal and molluscicidal activities of five Brazilian plants. Braz J Med Biol Res 2005; 38(12): 1873-78.
294. Mesquita ML, Desrivot J, Bories C, et al. Antileishmanial and trypanocidal activity of Brazilian Cerrado plants. Mem Inst Oswaldo Cruz 2005; 100(7): 783-87.
295. Abe F, Nagafuji S, Yamauchi T, et al. Trypanocidal constituents in plants 1. Evaluation of some Mexican plants for their trypanocidal activity and active constituents in Guaco, roots of Aristolochia taliscana. Biol Pharm Bull 2002; 25 (9): 1188-91.
296. Sulsen V, Guida C, Coussio J, Paveto C, Muschietti L, Martino V. in vitro Evaluation of trypanocidal activity in plants used in Argentine traditional medicine. Parasitol Res 2006; 98(4): 370-74.
297. Waechter AI, Cave A, Hocquemiller R, Bories C, Munoz V, Fournet A. Antiprotozoal activity of aporphine alkaloids isolated from Unonopsis buchtienii (Annonaceae). Phytother Res 1999; 13(2): 175-77.
298. Fevrier A, Ferreira ME, Fournet A, et al. Acetogenins and other compounds from Rollinia emarginata and their antiprotozoal activities. Planta Med 1999; 65(1): 47-49.
299. Schmeda-Hirschmann G, Astudillo L, Bastida J, et al. Cryptofolione derivatives from Cryptocarya alba fruits. J Pharm Pharmacol 2001; 53(4): 563-67.
300. Bonay P, Duran-Chica I, Fresno M, Alarcon B, Alcina A. Antiparasitic effects of the intra-Golgi transport inhibitor megalomicin. Antimicrob Agents Chemother 1998; 42(10): 2668-73.
301. Rolon M, Seco MN, Vega C, et al. Selective activity of polyene macrolides produced by genetically modified Streptomyces on Trypanosoma cruzi. Int J Antimicrob Agents. 2006; 28(2): 104-109.
302. Bastos JK, Albuquerque S, Silva ML. Evaluation of the trypanocidal activity of lignans isolated from the leaves of Zanthoxylum naranjillo. Planta Med 1999; 65(6): 541-44.
303. Luize PS, Ueda-Nakamura T, Filho BP, et al. Ultrastructural alterations induced by the neolignan eupomatenoid-5 on epimastigote and amastigote forms of Trypanosoma cruzi. Parasitol Res 2006; 29(10): 2126-30.
304. Tasdemir D, Kaiser M, Brun R, et al. Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies. Antimicrob Agents Chemother 2006; 50(4): 1352-64.
305. Batista R, Chiari E, de Oliveira AB. Trypanosomicidal kaurane diterpenes from Wedelia paludosa. Planta Med 1999; 65(3): 283-84.
306. Araya JE, Neira I, da Silva S, et al. Diterpenoids from Azorella compacta (Umbelliferae) active on Trypanosoma cruzi. Mem Inst Oswaldo Cruz 2003; 98 (3):413-18.
307. Kiuchi F, Matsuo K, Ito M, Qui TK, Honda G. New norditerpenoids with trypanocidal activity from Vitex trifolia. Chem Pharm Bull (Tokyo) 2004; 52(12): 1492-94.
308. Uchiyama N, Kabututu Z, Kubata BK, et al. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme. Antimicrob Agents Chemother 2005; 49(12): 5123-26.
309. Rubio J, Calderon JS, Flores A, Castro AC, Cespedes CL. Trypanocidal activity of oleoresin and terpenoids isolated from Pinus oocarpa. Z Naturforsch [C]. 2005; 60(9-10): 711-16.
310. Sanchez AM, Jimenez Ortiz V, Sartor T, et al. A novel icetexane diterpene, 5-epi-icetexone from Salvia gilliessi is active against Trypanosoma cruzi. Acta Tropica 2006; 98(2): 118-24.
311. Campos FR, Januario AH, Rosas LV, et al. Trypanocidal activity of extracts and fractions of Bertholletia excelsa. Fitoterapia. 2005; 76(1): 26-29.
312. Saednia S, Gohary AR, Ito M, Kiuchi F, Honda G. Bioactive constituents from Dracocephalum subcapitatum (O. Kuntze) Lipsky. N Naturforsch 2005; 60(1-2): 22-24.
313. Cunha WR, Crevelin EJ, Arantes GM, et al. A study of the trypanocidal activity of triterpene acids isolated from Miconia species. Phytother Res 2006; 20(6): 474-78.
314. Brengio SD, Belmonte SA, Guerreiro E, Giordano OS, Pietrobon EO, Sosa MA. The sesquiterpene lactone dehydroleucodine affects the growth of cultured epimastigotes of Trypanosoma cruzi. J Parasitol 2000; 86(2): 407-12.
315. Schmidt A, Kraugh-Siegel RL. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr Top Med Chem 2002; 2(11): 1239-59.
316. Jimenez-Ortiz V, Brengio SD, Giordano O, et al. The trypanocidal effect of sesquiterpene lactones helenalin and mexicanin on cultured epimastigotes. J Parasitol 2005; 91(1): 170-74.
317. Jordao CO, Vichenewsky W, de Souza GE, Albuquerque S, Lopes JL. Trypanocidal activity of chemical constituents from Lychnophora salicifolia. Mart. Phytother Res 2004; 18(4): 332-34.
318. Kiuchi F, Matsuo K, Ito M, Qui TK, Honda G. New sesquiterpene hydroperoxides with trypanocidal activity from Pogostemon cablin. Chem Pharm Bull (Tokyo) 2004; 52(12): 1495-96.
319. Grael CF, Albuquerque S, Lopez JL. Chemical constituents of Lychnophora pohlii and trypanocidal activity of crude plant extracts and of isolated compounds. Fitoterapia 2005; 76(1): 73-82.
320. Orhan I, Sener B, Atici T, Brun R, Perozzo R, Tasdemir D. Turkish freshwater and marine macrophyte extracts show in vitro antiprotozoal activity and inhibit FabI, a key enzyme of Plasmodium falciparum fatty acid biosynthesis. Phytomedicine 2006; 13(6): 388-93.
321. Bringmann, G., Rummey, C., Neumann, S., Brun, R., Stich, A., Hoerr, V., Mueller, W.E.G.: WO04067514A1 (2004).
322. Bringmann, G., Pfeifer, R.M., Brun, R., Muller, W.E.G.: WO04065349 ( 2004).
323. Bringman G, Hamm A, Gunther C, Michel M, Brun R, Mudogo V. Ancistroealaines A and B, two new bioactive naphthyl-isoquinolines, and related naphthoic acids from Ancistrocladus ealaensis. J Nat Prod 2000; 63 (11): 1465-70.
324. Buske, A., Kekule, A.S., Haring, A., Adam, G.: WO0300272A1 (2003).
325. Ferreira, M.E., Fournet, A., Rojas de Arias, A., Hocquemiller, R., Poupon, E.: WO04050092 A1 and WO04050092 B1 (2004).
326. Silva, M.L.A., Albuquerque, S., Souza, G.E.B., Bastos, J.K., Silva, R.: WO03080600A1 (2003).
327. De Souza VA, da Silva R, Pereira AC, et al. Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi. Bioorg Med Chem Lett 2005; 15(2): 303-07.
328. Cerecetto H, Gonzalez M. Chemotherapy of Chagas' disease: status and new developments. Curr Top Med Chem 2002; 2(11): 1187-213.
329. Ren H, Grady S, Banhart M, et al. Synthesis and in vitro anti-protozoal activity of a series of benzotropolone derivatives incorporating endocyclic hydrazines. Eur J Med Chem 2003; 38(12): 949-57.
330. Carvalho SA, da Silva EF, Santa-Rita RM, de Castro SL, Fraga CA. Synthesis and antitrypanosomal profile of new functionalized 1, 3, 4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorg Med Chem Lett 2004; 14(24): 5967-70.
331. De Souza EM, Lansiaux A, Bailly C, et al. Phenyl substitution of furamidine markedly potentiates its anti-parasitic activity against Trypanosoma Cruzi and Leishmania amazonensis. Biochem Pharmacol 2004; 68(4): 593-600.
332. De Souza EM, Mena-Barretto R, Araujo-Jorge TC et al. Antiparasitic activity of aromatic diamidines is related to apoptosis-like death in Trypanosoma cruzi. Parasitology 2006; 133(1):75-79.
333. Baliani A, Buene GJ, Stewart ML, et al. Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites. J Med Chem 2005; 48(17):5570-79.
334. Molfetta FA, Bruni AT, Honorio KM, da Silva AB. A structure-activity relationship study of quinone compounds with trypanocidal activity. Eur J Med Chem 2005; 40(4): 329-38.
335. Aguirre G, Boiani L, Cerecetto H et al. In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi 5-nitrofuryl containing thiosemicarbazones. Bioorg Med Chem 2004; 12(18): 4885-93.
336. Aguirre G, Cerecetto H, Di Maio R, et al. Quinoxaline N, N′-dioxide derivatives and related compounds as growth inhibitors of T. cruzi. Structure-activity relationships. Bioorg Med Chem 2004; 14(14): 3835-39.
337. Aguirre G, Boiani L, Cerecetto H, et al. [1, 2-c] 1, 2, 5-oxadiaxole N-oxide derivatives as potential antitrypanosomal drugs. Part 3: Substituents-clustering methodology in the search for new active compounds. Bioorg Med Chem 2005; 13(23): 6324-35.
338. Aguirre G, Boiani L, Boiani M, et al.. New potent 5-substituted benzofuroxans as inhibitors of [Trypanosoma cruzi growth: quantitative structure-activity relationship studies Bioorg Med Chem 2005; 13 (23): 6336-46.
339. Oliviera DA, Pereira DG, Fernandes AM, et al. Trypanocidal activity of 2-propen-1-amine derivatives on trypomastigotes culture and in animal model. Parasitol Res 2005; 95(3): 161-66.
340. Gerpe A, Aguirre G, Boiani L, et al. Indazole N-oxide derivatives as antiprotozoal agents: Synthesis, biological evaluation and mechanism of action studies. Bioorg Med Chem 2006; 14(10): 3467-80.
341. Boiani M, Boiani L, Denicola AJ, et al. 2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents. J Med Chem 2006; 49(11): 3215-24.
342. De Fatima A, Marquissolo C, de Albuquerque S, Carraro Abrahao AA, Pilli RA. Trypanocidal activity of 5, 6-dihydropyran-2-ones against free trypomastigotes forms of Trypanosoma cruzi. Eur J Med. Chem 2006; 41 (10): 1210-13.
343. Montero Torres A, Vega MC, Marrero Ponce Y, et al. A novel non-stochastic quadratic fingerprints-based approach for the 'in silico' discovery of new antitrypanosomal compounds 2005; 13(22): 6264-75.
344. Vega MC, Montero Torres A, Marrero Ponce Y, et al. New ligand-based approach for the discovery of antitrypanosomal compounds. Bioorg Med Chem Lett. 2006; 16(7): 1898-904.
345. Sas, B., Van Hemel, J., Vanderkerckhove, J.: WO04062590A2 and WO04062590A3 (2004).
346. Duran Caballero, N.E., Duran Haun, M.A., De Conti Lourenco, R.M., De Souza, A.O., Haun Quiros, N.M.: BR09805381A (2000).
347. Ahlem, C.N., Frincke, J.M, Prendergast, P.T.: WO0032201A2 and WO0032201A3 (2000).
348. Wyvratt, M.J., Biftu, T., Fisher, M.H., Schmatz, D.M.: WO04080390A2 and WO04080390A3 (2004).
349. Dardonville C. Recent advances in antitrypanosomal chemotherapy: patent literature 2002-2004.Expert opinion Ther Patents 2005; 15(9): 1241-57.